[
    [
        {
            "time": "",
            "orginal_text": "上海医药一季度业绩快速增长",
            "features": {
                "keywords": [
                    "上海医药",
                    "一季度",
                    "业绩",
                    "快速",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "上海医药一季度业绩快速增长",
            "scores": {
                "News_content": "上海医药一季度业绩快速增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "上海医药(601607)：业绩如期恢复 商业表现亮眼",
            "features": {
                "keywords": [
                    "上海医药",
                    "业绩",
                    "恢复",
                    "商业",
                    "表现",
                    "亮眼"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "上海医药(601607)：业绩如期恢复 商业表现亮眼",
            "scores": {
                "News_content": "上海医药(601607)：业绩如期恢复 商业表现亮眼",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "年报里的医药增长密码：集采疫情内外因素跌宕 创新药时代来临18家药企研发增超100%",
            "features": {
                "keywords": [
                    "年报",
                    "医药",
                    "增长",
                    "集采",
                    "疫情",
                    "创新药",
                    "研发",
                    "增长"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "年报里的医药增长密码：集采疫情内外因素跌宕 创新药时代来临18家药企研发增超100%",
            "scores": {
                "News_content": "年报里的医药增长密码：集采疫情内外因素跌宕 创新药时代来临18家药企研发增超100%",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "西南证券维持上海医药买入评级：Q1增长超预期，创新药即将步入收获期",
            "features": {
                "keywords": [
                    "西南证券",
                    "上海医药",
                    "买入评级",
                    "Q1",
                    "增长",
                    "超预期",
                    "创新药",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "西南证券维持上海医药买入评级：Q1增长超预期，创新药即将步入收获期",
            "scores": {
                "News_content": "西南证券维持上海医药买入评级：Q1增长超预期，创新药即将步入收获期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "每日“药”闻| 百济神州泽布替尼疗效超伊布替尼；微创医疗去年营收同比下滑18%",
            "features": {
                "keywords": [
                    "百济神州",
                    "泽布替尼",
                    "疗效",
                    "伊布替尼",
                    "微创医疗",
                    "营收",
                    "下滑"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "每日“药”闻| 百济神州泽布替尼疗效超伊布替尼；微创医疗去年营收同比下滑18%",
            "scores": {
                "News_content": "每日“药”闻| 百济神州泽布替尼疗效超伊布替尼；微创医疗去年营收同比下滑18%",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]